0001209191-19-002674.txt : 20190107 0001209191-19-002674.hdr.sgml : 20190107 20190107205120 ACCESSION NUMBER: 0001209191-19-002674 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190107 FILED AS OF DATE: 20190107 DATE AS OF CHANGE: 20190107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Manning Paul B CENTRAL INDEX KEY: 0001494695 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38529 FILM NUMBER: 19514541 MAIL ADDRESS: STREET 1: 200 GARRETT STREET SUITE S CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001660334 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463137900 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 484-453-3300 MAIL ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-07 0 0001660334 Verrica Pharmaceuticals Inc. VRCA 0001494695 Manning Paul B 200 GARRETT STREET, SUITE S CHARLOTTESVILLE VA 22902 1 0 1 0 Common Stock 2019-01-07 4 P 0 12775 10.41 A 8035658 D Common Stock 2019-01-07 4 P 0 20116 11.55 A 8055774 D Common Stock 2019-01-07 4 P 0 2734 11.99 A 8058508 D Common Stock 2019-01-07 4 P 0 4258 10.41 A 1299602 I See Footnote Common Stock 2019-01-07 4 P 0 6706 11.55 A 1306308 I See Footnote Common Stock 2019-01-07 4 P 0 911 11.99 A 1307219 I See Footnote Common Stock 256634 I See Footnote The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $9.87 to $10.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Consists of 7,754,783 shares of common stock held by Mr. Manning and 280,875 shares of common stock held by Mr. Manning jointly with his spouse. The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.98 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Consists of 7,754,783 shares of common stock held by Mr. Manning and 300,991 shares of common stock held by Mr. Manning jointly with his spouse. The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $11.98 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Consists of 7,754,783 shares of common stock held by Mr. Manning and 303,725 shares of common stock held by Mr. Manning jointly with his spouse. The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB. The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is President and CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI. /s/ Mark Ballantyne, Attorney-in-Fact 2019-01-07